The CHMP’s October Scorecard: Six Approvals, Five Expansions, and What the Patterns Reveal About EMA’s Evolving Evidence Bar

Open the EMA’s October meeting highlights and the first approval on the list stops you cold: daraxonrasib, branded Rasonque, cleared for adults with metastatic pancreatic adenocarcinoma who have already failed at least one prior line of therapy. Pancreatic cancer. A disease where median overall survival after first-line failure is measured in weeks, not months. The CHMP recommended it anyway, which means the committee looked at the evidence package for one of oncology’s most resistant tumor types and decided the benefit-risk balance cleared the bar.

Between October 12 and 15, 2026, the CHMP issued positive opinions on six new medicines and recommended five extensions of therapeutic indications for existing products. Eleven decisions in four days. Each one represents years of protocol design, patient enrollment, data collection, and regulatory strategy compressed into a committee vote. But the decisions themselves, read carefully, contain a curriculum in what the EMA currently accepts as sufficient evidence, and where the committee is pushing sponsors to do more.

That curriculum matters more now than it did twelve months ago, because the EMA adopted the ICH M11 Guideline on Clinical Electronic Structured Harmonised Protocol (CeSHarP) in December 2025, a framework designed to standardize how clinical trial protocols are created, reviewed, and shared across jurisdictions. Any sponsor who submitted a protocol before December 15, 2025 built it under different structural assumptions than any sponsor starting fresh today. The October decisions give the first real signal of how those assumptions translated into approval outcomes.

What Daraxonrasib Actually Proves

The daraxonrasib approval is the most operationally instructive decision in the October cycle, precisely because pancreatic adenocarcinoma is where trial design goes to die. The tumor microenvironment is immunosuppressive. Response rates to most targeted agents in this space hover in the single digits. The patient population deteriorates quickly, making long enrollment windows impossible. And yet the CHMP issued a positive opinion, which means the evidence package for Rasonque was structured in a way that satisfied the committee’s benefit-risk calculus under these conditions.

The mechanism here matters for sponsors designing trials in other solid tumor indications with similarly grim prognoses. A positive opinion in metastatic pancreatic adenocarcinoma after at least one prior therapy does not suggest the CHMP lowered its evidence bar. It suggests the committee applied its conditional marketing authorization framework, which allows approval on less-than-complete evidence when the disease is serious and unmet need is high, with the explicit understanding that post-authorization obligations will confirm the benefit-risk profile. Under EMA’s conditional authorization rules, those approvals are valid for one year and renewable annually, each renewal contingent on the holder meeting the specific post-authorization study requirements the CHMP attaches to the initial opinion.

This is the part sponsors frequently underestimate. Conditional approval feels like a finish line. The EMA treats it as a starting pistol for the next phase of evidence generation. A sponsor who reaches a positive opinion on a conditional basis and then under-resources the post-authorization confirmatory study is not coasting, they are accumulating risk that expires on a twelve-month clock.

Five Label Expansions and the Real Competitive Signal

The five indication extensions the CHMP recommended in the same cycle deserve as much attention as the six new approvals, arguably more. A label expansion in the EU means a sponsor returned to the CHMP with additional evidence for an already-approved product and convinced the committee to broaden its authorized use. Doing that successfully requires demonstrating that the original benefit-risk determination holds in the new population or indication, that the risk management plan on file under EMA’s GVP Module V framework has been updated to reflect new safety signals, and that the pharmacovigilance infrastructure is adequate for the expanded patient exposure.

Five successful expansions in one four-day session is not a coincidence. It reflects a deliberate regulatory strategy by the sponsors involved: build the original approval with the expansion pathway already mapped, design the initial clinical program to generate data that supports the next indication, and engage the CHMP early through scientific advice procedures rather than arriving with a completed dossier and hoping the committee agrees with your framing.

The EMA’s PRIME scheme, launched in 2016 as the EU analogue to the FDA’s Breakthrough Therapy designation, structured exactly this kind of iterative engagement. Medicines that enter the PRIME pathway get early dialogue with the CHMP, rolling review eligibility, and dedicated support for building the evidence package. Sponsors who used PRIME for their initial application arrived at this October cycle with a relationship with the committee, not just a dossier. The companies that collected expansion opinions in October almost certainly started planning those expansions before their first approval was finalized.

That sequencing is the counterintuitive insight buried in this October scorecard. The conventional assumption in clinical development holds that sponsors should focus on securing the initial approval before thinking seriously about indication expansion. The evidence from five simultaneous CHMP expansion opinions in one cycle suggests the opposite: sponsors who treat the initial trial program as a platform for future expansion, rather than a single-indication exercise, accumulate a structural advantage that compounds over time. By the time a competitor submits their first MAA, a platform-thinking sponsor is already in front of the CHMP with their second indication package.

Protocol Architecture in the Post-CeSHarP World

The ICH M11 CeSHarP guideline, effective December 15, 2025, changes the structural inputs into every CHMP review cycle from this point forward. The guideline mandates a standardized electronic protocol template designed to ensure consistency, efficiency, and interoperability in protocol creation, review, and cross-jurisdictional sharing. For sponsors running global trials where the same protocol supports both an FDA IND and an EMA Clinical Trial Application, this is operationally significant.

Consider what the October decisions reveal about the quality of protocol architecture the CHMP rewarded. Six new medicines crossed the approval threshold in a single cycle. Each of those programs generated clinical data the committee found sufficient. But sufficiency in 2026, under CeSHarP, means the protocol was built with structured, machine-readable fields that a reviewer can interrogate systematically, not a 200-page PDF that buries the primary endpoint definition on page 87. The standardization is designed to make review faster and more consistent. It also means that deviations from the template structure, gaps in the prespecified statistical analysis plan, or inconsistencies between the protocol synopsis and the full document text will surface earlier and more reliably than they did under the prior framework.

Sponsors who submitted protocols before December 2025 and are now approaching the CHMP with their first review cycle under CeSHarP face a specific operational challenge: their legacy protocol architecture may not map cleanly to the new structured template that reviewers are now trained to use. A protocol that satisfied a CHMP reviewer in 2023 is not automatically CeSHarP-compliant in 2026. The operational fix is not to rewrite the protocol from scratch, but to conduct a structured gap analysis against the ICH M11 template before the next regulatory submission, identify where the existing document structure diverges from the standardized format, and either reconcile those gaps in the submission package or address them proactively in the cover letter.

The daraxonrasib approval, sitting at the top of the October list, is also a reminder that the CHMP’s benefit-risk framework accommodates uncertainty when the disease context justifies it. But that accommodation comes with post-authorization strings attached, a pharmacovigilance infrastructure requirement, an annual renewal contingency, and a confirmatory study obligation that the sponsor must resource adequately. Treating a conditional opinion as equivalent to a full approval is the most expensive misreading a development team can make.

Eleven decisions in four days. The sponsors who will be back in front of the CHMP with their next expansion package twelve months from now are the ones who read October’s scorecard not as a news item, but as a protocol review.

References

1. European Medicines Agency, “Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12–15 October 2026”
2. European Medicines Agency, “ICH M11 Guideline on Clinical Electronic Structured Harmonised Protocol (CeSHarP): Protocol Template and Technical Specifications”
3. European Medicines Agency, “Conditional Marketing Authorisation: Post-Authorization Obligations and Annual Renewal Requirements”
4. European Medicines Agency, “Risk Management Plans: GVP Module V Requirements for Marketing Authorization Holders”
5. CASRAI, “EMA PRIME Scheme Eligibility: 2026 Pilot Overview”